Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer

Exclusion Criteria

• •Pregnancy or lactation
• •SGOT and/or SGPT \> 1.5 upper limit normal, associated with Alk.phosph \> 2.5 ULN
• •Serious medical condition including but not limited to:
• •Uncontrolled hypertension
• •Active ulcus pepticum
• •Non-stable diabetes mellitus
• •Other contraindication of steroid treatment
• •Myocardial infarction within the last 6 months prior study entry
• •Significant neurologic/psychiatric disorders
• •Active infection
• •Peripheral neuropathy grade ≥ 2
• •Unstable angina
• •Severe arrhythmia
• •Participation in other clinical trial
• •Prior surgery, chemotherapy, hormonotherapy for breast cancer
• •Past or current history of neoplasm other than breast cancer, except for: curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, other cancer curatively treated and with no evidence of disease for at least 7 years
• •History of hypersensitivity to the investigational products or to drugs with similar chemical structures
• •Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol
• •Treatment with any investigational product in the last 1 month before study entry.
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.